Recombinant avian infectious coryza vaccine and process for preparing same
View Patent ↗A recombinant avian infectious coryza vaccine and a process for preparing the same are provided. A process for preparing a recombinant avian infectious coryza vaccine which comprises step of constructing E. coli that may produce as an inclusion body a fusion peptide consisting of peptides derived from outer-membrane protein of Avibacterium paragarinarum serotype A and serotype C, step of culturing said E. coli and collecting and purifying inclusion body from culture, and step of preparing a preparation comprising said purified inclusion body, and an avian infectious coryza vaccine comprising as an active ingredient the fusion peptide. A linker sequence may be inserted between the respective peptides comprising the fusion peptide. For the peptide derived from the serotypes A and C, an amino acid sequence region of Region 2 or its vicinity responsible for protection from infection may be used.
1. A process for preparing a recombinant avian infectious coryza vaccine, comprising: constructing a host that can produce as an inclusion body a fusion peptide comprising a peptide fragment (Peptide A) derived from HMTp210 protein of A.pg -A, wherein peptide A comprises the amino acid sequence of SEQ ID NO:35, and a peptide fragment (Peptide C) derived from HMTp210 protein of A.pg -C, wherein Peptide C comprises the amino acid sequence of SEQ ID NO:56; culturing the host and collecting and purifying a fraction of inclusion body from culture, to obtain a purified fraction of inclusion body; and preparing a preparation comprising the purified fraction of inclusion body, wherein Peptide A and Peptide C consist of 600 or less amino acid residues.
2. The process of claim 1 , wherein Peptide A or Peptide C comprises an amino acid sequence where one or several amino acids are deleted, added, or replaced.
3. The process of claim 1 , wherein a ratio of Peptide A and Peptide C in the fusion peptide is 1 to 3 of Peptide C to 1 of Peptide A.
4. The process of claim 1 , wherein the fusion peptide comprises at least a structure where Peptide C is linked to the C-terminal of Peptide.
5. The process of claim 1 , wherein the fusion peptide comprises a linker between Peptide A and Peptide A, Peptide C and Peptide C, or Peptide A and Peptide C.
6. The process of claim 1 , wherein the fusion peptide comprises the amino acid sequence of SEQ ID NO:9.
7. A recombinant avian infectious coryza vaccine, comprising as an active ingredient a fusion peptide comprising a peptide fragment (Peptide A) derived from HMTp210 protein of A.pg -A, wherein peptide A comprises the amino acid sequence of SEQ ID NO:35, and a peptide fragment (Peptide C) derived from HMTp210 protein of A.pg -C, wherein Peptide C comprises the amino acid sequence of SEQ ID NO:56,
wherein Peptide A and Peptide C consist of 600 or less amino acid residues.
8. The vaccine of claim 7 , wherein Peptide A or Peptide C comprises an amino acid sequence where one or several amino acids are deleted, added, or replaced.
9. The vaccine of claim 7 , wherein a ratio of Peptide A and Peptide C in the fusion peptide is 1 to 3 of Peptide C to 1 of Peptide A.
10. The vaccine of claim 7 , wherein the fusion peptide comprises at least a structure where Peptide C is linked to the C-terminal of Peptide.
11. The vaccine of claim 7 , wherein the fusion peptide has a linker between Peptide A and Peptide A, Peptide C and Peptide C, or Peptide A and Peptide C.
12. The vaccine of claim 7 , wherein the fusion peptide comprises the amino acid sequence of SEQ ID NO:9.
13. A recombinant avian infectious coryza vaccine, comprising as an active ingredient a peptide that consists of an amino acid sequence within the amino acid sequence of SEQ ID NO:1 and comprises the amino acid sequence of SEQ ID NO: 35 with addition of 1 to 200 amino acid residues at at least one selected from the group consisting of the N-terminal and the C-terminal thereof.
14. The vaccine of claim 13 , further comprising as an active ingredient, a peptide consisting of the amino acid sequence of SEQ ID NO: 1.
15. A recombinant avian infectious coryza vaccine, comprising as an active ingredient a peptide that consists of an amino acid sequence within the amino acid sequence of SEQ ID NO:3 and comprises the amino acid sequence of SEQ ID NO: 56,
with addition of 1 to 200 amino acid residues at at least one selected from the group consisting of the N-terminal and the C-terminal thereof.
16. The vaccine of claim 15 , further comprising, as an active ingredient, a peptide consisting of the amino acid sequence of SEQ ID NO: 3 or 52.
17. The vaccine of claim 14 or 16 , wherein the peptide comprises an amino acid sequence wherein one or several amino acids are deleted, added, or replaced.
18. The process of claim 1 , wherein the fusion peptide is either (1) or (2) as follows:
(1) a fusion peptide comprising a combination of Peptide A consisting of the amino acid sequence of SEQ ID NO: 1 and Peptide C consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 3, 4, 5, 6, 7, 50, 51, 52, 53, 54, and 56; or
(2) a fusion peptide comprising a combination of Peptide C consisting of the amino acid sequence of SEQ ID NO: 3 and Peptide A consisting of the amino acid sequence of SEQ ID NO:35.
19. The process of claim 1 , wherein the fusion peptide has the amino acid sequence of SEQ ID NO:49.
20. The process of claim 1 , wherein the fusion peptide has the amino acid sequence of SEQ ID NO: 12.
21. The vaccine of claim 7 , wherein the fusion peptide is either (1) or (2) as follows:
(1) a fusion peptide comprising a combination of Peptide A consisting of the amino acid sequence of SEQ ID NO: 1 and Peptide C consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 3, 4, 5, 6, 7, 50, 51, 52, 53, 54, and 56; or
(2) a fusion peptide comprising a combination of Peptide C consisting of the amino acid sequence of SEQ ID NO: 3 and Peptide A consisting of the amino acid sequence of SEQ ID NO:35.
22. The vaccine of claim 7 , wherein the fusion peptide comprises the amino acid sequence of SEQ ID NO:49.
23. The vaccine of claim 7 , wherein the fusion peptide comprises the amino acid sequence of SEQ ID NO: 12.